Christa H. Nyhus
Vejle, 7100, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
The prognostic potential of an immunology score in patients treated with curative surgery for non-small cell lung cancer.
Journal: Journal of cancer research and clinical oncology
Published: April 15, 2026
The prognostic value of methylated ctDNA, soluble PD-L1, and NK-cell activity on the risk of relapse after curative radiotherapy of non-small cell lung cancer.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: October 21, 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 07, 2025
Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.
Journal: Scientific reports
Published: December 08, 2023
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan.
Journal: Acta oncologica (Stockholm, Sweden)
Published: November 07, 2023
NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Journal: British journal of cancer
Published: May 05, 2022
The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer.
Journal: Translational lung cancer research
Published: March 15, 2021
Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial.
Journal: Clinical and translational radiation oncology
Published: June 09, 2020
Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: March 16, 2017
A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60Gy and 66Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: September 29, 2016
Last Updated: 09/26/2026